MRI Invisible Prostate ca: Risk Pathway

on
MRI-Invisible Prostate Cancer: A Risk-Stratified Framework

MRI-Invisible Prostate Cancer

A Risk-Stratified Framework to Diagnose Clinically Significant Disease Without Fueling Over-Treatment.

MDT Ready NICE NG131 Aligned PRECISION Logic

Author: Dr. Sharad Maheshwari, imagingsimplified@gmail.com

🛑 The Governance Challenge

The "MRI-invisible" scenario (PI-RADS 1-2) is a critical junction. The Trap: Clinicians mistakenly equate MRI-negative with cancer-negative, or conversely, biopsy everyone "just in case."

Our Objective: Find what matters. Leave the rest alone.

  • ✖ Avoid: Reflex biopsies in low-risk men.
  • ✖ Avoid: Discharging high-risk men without safety netting.
  • ✔ Goal: Prevent missed clinically significant PCa (csPCa).

📌 Operational Definitions

MRI-Invisible Entry Criteria

mpMRI shows PI-RADS/Likert 1–2, OR no reproducible focal lesion for targeting.

Clinically Significant (csPCa)

ISUP Grade Group ≥2 (Gleason ≥3+4) OR Cancer volume sufficient for radical therapy.

CRITICAL:

We do not build systems to "find every cancer." We build systems to find the cancers that matter.

The Evidence Spine

Understanding the landmark studies that shifted us from "blind biopsy" to "risk-stratified targeting". Click cards for clinical interpretation.

PROMIS

Lancet 2017

mpMRI as Triage

Validated MRI's role in ruling out csPCa better than TRUS.

"MRI is the best first-line imaging triage we have—but it is not absolute."

Click for details ▼

PRECISION

NEJM 2018

Targeted vs Standard

MRI-targeting detects more csPCa and less insignificant disease.

"When MRI gives a lesion, target it. When negative, don't pretend targeting exists—shift to risk-driven logic."

Click for details ▼

NICE NG131

UK Guidelines

The Safety Net

MRI-negative does not mean "do nothing". It means "Assess Risk".

"Anchor escalation to PSA density (>0.15) and velocity (>0.75), not anxiety."

Click for details ▼

The Conceptual Shift

PRECISION & PROMIS demonstrated that an MRI-First pathway alters diagnostic yield. We catch more of what harms (csPCa) and less of what doesn't (Low Risk).

Why this matters: In the MRI-negative patient, we must maintain this discipline. Randomly biopsying everyone reverts us to the "Traditional" column—high over-detection.

🧮 MRI-Negative Risk Stratifier

Input patient parameters to determine the escalation strategy (Surveillance vs Biopsy).

Clinical Inputs

Negative (PI-RADS 1-2 / No Target)
*Parameters based on NICE NG131 & Clinical Best Practice
LOW RISK

Monitor (Active Surveillance)

No immediate biopsy indicated. PSA stable, density low, and MRI negative. Risk of csPCa is minimal.

Governance Protocol:

  • Repeat PSA at 3–6 months.
  • Set explicit re-referral thresholds.
  • Do not discharge without safety net.

The Risk-Stratified Algorithm

Step-by-step management of the MRI-Negative Patient

1

1. Quality Check

Review PI-RADS 1-2. Confirm technical adequacy. Consider second read if discordance exists.

2. Risk Calculation

Calculate PSA Density (Target <0.15) and PSA Velocity (Target <0.75). Check Family Hx.

2
3

3. Decision: Biopsy vs Monitor

Low Risk: Surveillance with triggers.
High Risk: Transperineal Biopsy (Systematic + Anterior).

4. Treatment / Exit

Cancer Found? Treat based on Grade Group. Avoid radical treatment for GG1.

No Cancer? Safety net plan. PSA recheck 3-6mo.

4

💉 Biopsy Strategy

When MRI is negative, you lose targeting advantage. Success depends on route and coverage.

  • 1. Transperineal is Baseline: Modern standard. Avoid transrectal risks and poor anterior sampling.
  • 2. Anterior Sampling: Essential in MRI-negative men (anterior tumours often under-sampled).

🚫 "What We Stop Doing"

A serious unit must formally stop the following behaviors:

  • STOP "MRI negative, therefore safe forever." (False)
  • STOP "MRI negative, therefore biopsy everyone." (Over-diagnosis)
  • STOP Treating PSMA uptake as histology.
  • STOP Radical therapy for GG1 disease due to patient anxiety.

Comments

Post a Comment